Tirzepatide Reduces Fat Mass and Provides Good Glycaemic Control in Type 2 Diabetes Patients Undergoing Haemodialysis: A Single‐Centre Retrospective Study

<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Objective</jats:title><jats:p>Tirzepatide is an injectable peptide approved by the US Food and Drug Administration for the treatment of Type 2 diabetes (T2DM). Its weight‐loss effect primarily targets fat reduction; however, such effect on patients with chronic kidney disease (CKD) undergoing haemodialysis (HD) has not been reported.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Nine patients with CKD undergoing HD received weekly tirzepatide doses (2.5–7.5 mg) once a week. Evaluations encompassed tirzepatide's impact on dry weight (DW) and body composition assessed at baseline and study conclusion using bioelectrical impedance analysis. This longitudinal study included nine patients, with a median age of 53 years and median HD duration of 4 years.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Tirzepatide treatment significantly decreased glycated albumin compared with the value at baseline (22.7 ± 5.4 vs. 18.3 ± 2.5%, <jats:italic>p</jats:italic> = 0.028, respectively). Significant reductions were observed in DW (−1.0 kg, <jats:italic>p</jats:italic> = 0.024) and body mass index (−0.6 kg/m<jats:sup>2</jats:sup>, <jats:italic>p</jats:italic> = 0.050) following tirzepatide administration. Total fat mass was also reduced, but not significantly (− 2.51% from baseline, <jats:italic>p</jats:italic> = 0.214). In contrast, skeletal muscle mass was not decreased (−1.02% from baseline, <jats:italic>p</jats:italic> = 0.722). No serious side effects other than nausea were observed during the study period.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Tirzepatide effectively provides good glycaemic control in T2DM patients undergoing HD, decreasing DW by reducing body fat mass without increasing frailty risk.</jats:p></jats:sec>